WuXi AppTec Co (603259.SS) Osake Kurssi
WuXi AppTec Co Kurssi
Liikevaihto on kasvanut 24,3 % vuodessa viimeisten 11 vuoden aikana 45,46 Mrd. CNY:een. Osakekohtainen tulos on kasvanut 40,3 % vuodessa viimeisten 11 vuoden aikana. WuXi AppTec Con nettomarginaali on nyt 42,1 %, noussut 22,3 %:sta muutama vuosi sitten. WuXi AppTec Con osinkotuotto on tällä hetkellä noin 1,18 %. Jakosuhde on noin 21 % tuloksesta. Osinko on kasvanut 37,7 % vuodessa viimeisten 6 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 132,60 CNY, eli ali nykyhintaa 7,1 %. 25 analyytikosta 23 suosittaa ostoa — kokonaiskonsensus on Osta.
WuXi AppTec Co osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
WuXi AppTec Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset WuXi AppTec Co -osakkeesta
WuXi AppTec Co Ltd is primarily present in multiple countries and regions globally. Some of the key locations where the company has a significant presence include China, the United States, Germany, the United Kingdom, Japan, and Singapore. With a wide network of operations and collaborations, WuXi AppTec has established itself as a leading global pharmaceutical, biotechnology, and medical device company. Through its extensive presence and expertise, the company aims to provide innovative solutions and support to its clients in the healthcare industry across various markets.
The business model of WuXi AppTec Co Ltd is focused on providing comprehensive R&D services and integrated platform solutions for the pharmaceutical, biotechnology, and medical device industries. With a customer-centric approach, WuXi AppTec offers a wide range of services, including discovery, development, and manufacturing of drugs and medical devices. By leveraging its expertise in research, development, and manufacturing, along with its global network of facilities and technologies, WuXi AppTec aims to enable its customers to accelerate the discovery and development of innovative therapies and improve the overall efficiency of the drug development process.
WuXi AppTec Co Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of WuXi AppTec Co Ltd in the market include Charles River Laboratories International Inc., Eurofins Scientific SE, LabCorp, and PPD Inc.
WuXi AppTec Co Ltd is a leading global pharmaceutical and biotechnology company. Founded in China in 2000, the company has grown to become a key player in the life sciences industry. WuXi AppTec provides a wide range of services to support drug research and development, including laboratory testing, manufacturing, and biologics services. With a focus on innovation and quality, the company has established strategic collaborations with numerous pharmaceutical companies and research institutions worldwide. WuXi AppTec has received multiple recognitions and awards for its contributions to the healthcare industry. Today, it continues to expand its global presence and drive advances in drug discovery and development.
WuXi AppTec Co Ltd, a leading global pharmaceutical company, has achieved several significant milestones. The company has established itself as a leader in providing comprehensive and integrated research and development services to enable the discovery and development of innovative drugs. WuXi AppTec has expanded its global footprint and now operates in over 30 countries. The company has also made progress in advancing precision medicine and has collaborated with industry leaders to accelerate drug development. WuXi AppTec's commitment to innovation and collaboration has contributed to its success in becoming a trusted partner for the biopharmaceutical industry.
WuXi AppTec Co Ltd is a leading global pharmaceutical and biopharmaceutical open-access capability and technology platform company. It is committed to providing a broad portfolio of R&D and manufacturing services to help accelerate the discovery, development, and commercialization of innovative medicines. WuXi AppTec follows a corporate philosophy that emphasizes integrity, innovation, and collaboration. With a focus on quality and excellence, the company strives to create value for its customers, partners, and shareholders. WuXi AppTec Co Ltd's commitment to scientific expertise, customer-centricity, and continuous improvement reflects its dedication to advancing healthcare solutions and making a positive impact on society.
Analyytikot asettavat tällä hetkellä WuXi AppTec Co-osakkeelle keskimääräisen tavoitehinnan 130,66 CNY (mediaani: 132,60 CNY), mikä merkitsee −8,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 25 analyytikkoarvioon.
25 analyytikkoa arvioi tällä hetkellä WuXi AppTec Co-osaketta: 23 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat WuXi AppTec Co-yhtiöltä 60,12 Mrd. CNY liikevaihtoa ja 9,17 CNY osakekohtaista tulosta.
Nykyisellä valuuttakurssilla WuXi AppTec Co-osake noteerataan hintaan 19,01 EUR (142,66 CNY).
WuXi AppTec Co-osake (603259.SS) on listattuna 1 pörssissä, muun muassa: Shanghai (603259.SS).
WuXi AppTec Co Ltd is a global biotechnology and pharmaceutical company based in China. It was founded in 2000 and has built a wide portfolio of services in the areas of research and development, as well as manufacturing. The company is divided into various business divisions, including laboratory services, research and development, clinical trials, manufacturing and packaging, and services for biotech and pharmaceutical companies. It offers a range of services in laboratory services, such as chemical and biological analysis, preclinical safety and efficacy testing, as well as cellular and molecular biology. In the research and development area, the company works closely with its customers to develop new compounds and therapies. It also provides clinical trial services to test the effectiveness and safety of new drugs. Additionally, WuXi AppTec offers comprehensive manufacturing and packaging services and a range of consulting and support services. Overall, the company aims to support the research and development of new therapies and drugs, with a focus on quality and customer satisfaction.
odotettu liikevaihto WuXi AppTec Co on 60,12 Mrd. CNY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto WuXi AppTec Co on 22,03 Mrd. CNY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
WuXi AppTec Co:n hinta-voitto-suhde (P/E) on tällä hetkellä 15,55. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan WuXi AppTec Co-osakkeen arvostusta.
WuXi AppTec Co:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,70. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii WuXi AppTec Co-osakkeen arvostuskennuslukuna.
WuXi AppTec Co:n Eulpool-laatuscore on 7/10.
WuXi AppTec Co:n ISIN on CNE1000031K4. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
WuXi AppTec Co:n ticker on 603259.SS. Tämä pörssinoteeraus käytetään WuXi AppTec Co-osakkeiden kauppaan pörssissä.
WuXi AppTec Co osake
WuXi AppTec Co vertaisryhmä
WuXi AppTec Co Ticker
WuXi AppTec Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi WuXi AppTec Co:sta
Meidän osakeanalyysimme WuXi AppTec Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut WuXi AppTec Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: